A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke

Trial Profile

A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Sponsors Stemedica Cell Technologies
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 May 2016 to 1 Dec 2017.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2017.
    • 27 Jan 2016 According to Stemedica Cell Technologies media release, company is planning to submit data from this trial to the FDA for a fast-track designation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top